The U.S. Food and Drug Administration’s ongoing review of modified risk tobacco product (MRTP) applications for ZYN nicotine pouches represents a pivotal moment in the regulation of non-combustible nicotine. At stake is not whether nicotine products are “safe,” but whether regulators will permit carefully constrained, evidence-based communication about relative risk compared with cigarette smoking. The…
Nicotine policy is increasingly being shaped not only by legislators and regulators, but by the channels through which products are made available to adults. In several countries, pharmacies have emerged as a focal point in this debate, acting either as formal gatekeepers of access or as trusted retail environments for smoke-free nicotine products. How pharmacists…
The European Commission has confirmed that the EU Tobacco Policy Expert Group (TPEG) will formally conclude its mandate, even as work on the next revision of the Tobacco Products Directive (TPD) continues. While the end of a technical advisory body may appear procedural, it raises important questions about how expertise, evidence, and stakeholder input will…
Nicotine pouches continue to expand across multiple markets, even as regulatory scrutiny intensifies and public debate grows more polarised. This sustained growth is not accidental, nor is it driven by novelty alone. It reflects a convergence of behavioural, commercial, and policy dynamics that are reshaping how adult nicotine users move away from combustible cigarettes. For…
Nicotine pouches are no longer a niche or experimental category. Retail and market indicators now show sustained growth across major U.S. convenience channels, reinforcing a reality that regulators globally can no longer ignore: consumer uptake is happening faster than policy alignment. Recent U.S. retail reporting highlights accelerating sales, expanding shelf presence, and increasing manufacturer investment…
Nicotine pouches are increasingly discussed as a distinct category within the broader harm-reduction landscape, raising important questions about how they should be regulated, communicated, and positioned relative to smoking cessation tools. A recent commentary in The Lancet Public Health provides a timely and balanced lens through which to assess these questions, particularly as policy debates…
In recent months, Argentina has emerged as an unexpected focal point in the global debate over nicotine pouches, harm reduction, and regulatory coherence. As international brands begin to enter the market and attract consumer attention, provincial authorities have moved quickly to restrict nicotine pouches using existing tobacco-control frameworks. The result is a familiar tension seen…
Across Europe, policymakers continue to express concern that fragmented nicotine regulation is leaving young people exposed to risk. Recent commentary has pointed to uneven national rules governing nicotine pouches, vapes, and other novel products as evidence that current policy approaches are failing to protect youth. While these concerns are legitimate, fragmentation itself is not the…
A GINN response to “The war on snus” The Cyprus Mail article “The war on snus” highlights a regulatory paradox that is becoming increasingly familiar across Europe: nicotine pouches are treated as an urgent public-health threat, while combustible cigarettes remain legally available, widely sold, and socially embedded. From a GINN perspective, the issue is not…
Recent analysis published in The Lancet Public Health reinforces a long-standing but often overlooked reality in tobacco control: nicotine use is not a monolith, and public-health outcomes depend critically on how nicotine is delivered. Policies that fail to distinguish between combustible and non-combustible products risk undermining smoking reduction goals, particularly among adults who continue to…